Recent 8-K filings for SER

• May 14, 2026 20:05 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

  Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.

• Apr 21, 2026 23:59 UTC leadership materiality 0.35 neutral item 5.02item 5.03item 9.01

  Serina appoints CTO, raises CEO salary to $500K, amends bylaws for Co-Chairs

  Srini Tenjarla, Ph.D., promoted to CTO of Serina (AL) subsidiary; salary increased to $425,000 retroactive to Mar 15, 2026.

• Mar 25, 2026 23:59 UTC earnings materiality 0.75 neutral item 2.02item 9.01

  Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed

  Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.

• Mar 23, 2026 23:59 UTC other_material materiality 0.85 positive item 1.01item 3.02item 5.02item 5.03item 7.01item 9.01

  Serina raises $15M first tranche (up to $30M) at $2.25/share (68% premium); Greg Bailey appointed Co-Chairman

  First tranche of $15M closed March 20, 2026; second tranche up to $15M due by April 30, 2026.

• Jan 28, 2026 23:59 UTC regulatory materiality 0.75 positive item 8.01item 9.01

  Serina Therapeutics receives FDA clearance for SER-252 IND in advanced Parkinson's

  FDA cleared IND for SER-252, an investigational therapy for advanced Parkinson's disease.

• Jan 15, 2026 23:59 UTC regulatory materiality 0.75 negative item 3.01item 7.01item 9.01

  Serina Therapeutics receives NYSE American deficiency notice for stockholders' equity below $2M

  Stockholders' equity was $1.6M as of Sept 30, 2025, below $2M, $4M, and $6M thresholds.

• Dec 10, 2025 23:59 UTC regulatory materiality 0.70 neutral item 8.01item 9.01

  Serina submits complete response to FDA clinical hold for SER-252 Parkinson's program

  Complete response submitted Dec 9, 2025, addressing FDA's clinical hold on SER-252 related to trehalose excipient.

• Nov 13, 2025 23:59 UTC earnings materiality 0.75 negative item 2.02item 9.01

  Serina Therapeutics Q3 net loss $4.6M; FDA places SER-252 on clinical hold

  Net loss of $4.6M ($0.45 per share) vs net income of $1.4M in Q3 2024.

• Nov 12, 2025 23:59 UTC other_material materiality 0.20 neutral item 5.07item 9.01

  Serina Therapeutics stockholders elect directors and ratify auditors at 2025 annual meeting

  Steve Ledger and Karen J. Wilson elected as directors with over 4.1M votes For each.

• Nov 03, 2025 23:59 UTC regulatory materiality 0.85 negative item 8.01item 9.01

  Serina Therapeutics announces FDA clinical hold on SER-252 IND for advanced Parkinson's disease

  FDA placed clinical hold on SER-252 IND, requesting additional info on a commonly used excipient; not related to active drug or mechanism.

• Oct 06, 2025 23:59 UTC other_material materiality 0.65 positive item 8.01item 9.01

  Serina Therapeutics draws first $5M tranche from $20M note for SER-252 Parkinson's trial

  Received $5 million initial tranche under up to $20 million convertible note financing agreement.

• Sep 15, 2025 23:59 UTC debt materiality 0.65 neutral item 1.01item 2.03item 3.02item 9.01

  Serina Therapeutics enters up to $20M convertible note from director Gregory H. Bailey for clinical study SER-252-1b

  Up to $20M drawn in 5 tranches tied to milestones for SER-252-1b registrational study; $5M available by Sept 30, 2025.

• Sep 09, 2025 23:59 UTC debt materiality 0.65 positive item 7.01item 9.01

  Serina Therapeutics Secures Up to $20M in Convertible Note for Parkinson's Trial

  Unsecured convertible note up to $20M in five tranches tied to clinical milestones; first $5M available by Oct 1, 2025.

• Aug 25, 2025 23:59 UTC other_material materiality 0.70 positive item 8.01item 9.01

  FDA feedback supports registrational trial for SER-252 in advanced Parkinson's under 505(b)(2) NDA pathway

  FDA Type B meeting written feedback supports advancing SER-252 (POZ-apomorphine) in registrational study.

• Aug 22, 2025 23:59 UTC other_material materiality 0.25 neutral item 5.03item 9.01

  Serina Therapeutics amends bylaws to add safe harbor procedures and expand forum selection clause

  Board adopted Bylaws Amendment on August 18, 2025, effective immediately.

• Aug 11, 2025 23:59 UTC earnings materiality 0.60 negative item 2.02item 9.01

  Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year

  Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).

• Jul 29, 2025 23:59 UTC other_material materiality 0.55 positive item 7.01item 9.01

  Serina advances SER-270 (POZ-VMAT2i) once-weekly injectable into TD development

  SER-270 is a long-acting, once-weekly subcutaneous VMAT2 inhibitor for tardive dyskinesia (TD).

• Jul 01, 2025 23:59 UTC other materiality 0.10 neutral item 5.08item 8.01item 7.01item 9.01

  Serina Therapeutics sets 2025 annual meeting for Nov 7; updates proposal deadlines

  Annual meeting scheduled for November 7, 2025; location and time in proxy.

• May 22, 2025 23:59 UTC leadership materiality 0.65 neutral item 5.02item 5.03item 7.01item 9.01

  Serina appoints ex-Karuna CMO Brannan to board; director Gross departs

  Appointed Dr. Stephen Brannan (former Karuna CMO) to board and Compensation Committee, effective May 22, 2025.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.65 · Most common event other_material

6 positive 4 negative 9 neutral

source · SER on sec.gov